A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

Anna Minchom(Royal Marsden NHS Foundation Trust), Udai Banerji(Institute of Cancer Research)

PLoS ONE

October 5, 2017

10.1371/journal.pone.0186106

Cited by 16

Related Papers

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

|The Lancet Oncology|2019|564

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

|The Lancet Oncology|2023|195

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

|Clinical Cancer Research|2013|160

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

|Cancer Discovery|2020|134

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

|Clinical Cancer Research|2014|47